| Grant ID | DP250137 |
| Awarded On | November 20, 2024 |
| Title | Revolutionizing Solid Tumor Therapy with Bispecific TCRm Antibodies Targeting Intracellular Cancer Targets |
| Program | Product Development Research |
| Award Mechanism | Seed Awards for Product Development Research |
| Institution/Organization | Ypsilon Therapeutics |
| Principal Investigator/Program Director | Dongxing Zha |
| Cancer Sites | Breast, Lung and Bronchus, Stomach |
| Contracted Amount |
$2,727,500* *Pending contract negotiation |
| Lay Summary |
Despite the clinical response to immunotherapy, many cancer patients fail to respond to the immune checkpoints. Ypsilon's lead CT83 program is a promising therapy that can eliminate CT83 antigen-expressing cancer leaving normal tissue untouched. Using a cutting-edge technology, we have a unique the biologics-based asset that can tackle undruggable targets and redirect the body's own immune system to fight the cancer. The estimated 600k patients die from cancer each year. Ypsilon set out to tackling some of the most high-need cancers: NSCLC, TNBC, and gastric cancer. Breakthroughs in these indications can directly impact patients who have no other treatment options. The goal of Ypsilon's wo... |